Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
41 studies found for:    " February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Raltegravir Activity In Lymphoid Tissues
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Efavirenz + Tenofovir DF/Emtricitabine;   Drug: Raltegravir + Tenofovir DF/Emtricitabine;   Procedure: Colonoscopy with biopsies;   Procedure: Inguinal Lymph Node Excision
2 Completed
Has Results
Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
Conditions: HIV Infection;   HIV Infections
Intervention: Drug: Raltegravir
3 Completed Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Conditions: Acute HIV Infection;   HIV Infections
Intervention: Drug: Darunavir/Ritonavir and Etravirine
4 Completed The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
Conditions: HIV Positive;   Opioid Dependence;   Opioid Agonist Treatment;   HIV Infections
Intervention:
5 Completed Evaluating Post-test HIV Counseling Videos for Teens
Conditions: HIV;   HIV Infections
Intervention: Behavioral: Video
6 Completed A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers
Conditions: HIV;   HIV Infections
Interventions: Biological: Ad35-GRIN/ENV;   Biological: Ad35-GRIN
7 Recruiting A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: Darunavir;   Drug: Ritonavir;   Drug: Etravirine;   Drug: Rilpivirine;   Drug: Darunavir/Cobicistat (FDC)
8 Completed
Has Results
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
Conditions: Amphetamine-Related Disorders;   HIV;   HIV Infections
Interventions: Drug: Truvada;   Behavioral: CM
9 Completed Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Conditions: HIV;   HIV Infections
Interventions: Biological: V526;   Biological: Comparator: Placebo to V526
10 Completed Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Be Proud! Be Responsible!;   Behavioral: Becoming A Responsible Teen (BART);   Behavioral: Reducing the Risk
11 Active, not recruiting Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?
Conditions: HIV Infection;   Herpes Simplex Type II;   HIV Infections
Interventions: Drug: valacyclovir;   Drug: Placebo
12 Withdrawn Pharmacotherapy for HIV Infected Patients With Alcohol Problems
Conditions: HIV Infection;   Heavy Alcoholic Consumption;   HIV Infections
Intervention: Drug: Naltrexone
13 Completed Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome
Conditions: HIV (Human Immunodeficiency Virus);   Metabolic Syndrome;   HIV Infections
Intervention: Behavioral: Dietary Intervention
14 Completed Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: AZT+3TC+ABV (Trizivir);   Drug: Switching to LPV/r monotherapy (Kaletra)
15 Terminated
Has Results
Minocycline for HIV+ Cognitive Impairment in Uganda
Conditions: HIV-associated Cognitive Impairment;   HIV Infections
Interventions: Drug: minocycline;   Drug: minocycline placebo capsule
16 Active, not recruiting Strategic Timing of Antiretroviral Treatment
Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
17 Completed Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: darunavir;   Drug: Ritonavir;   Drug: Etravirine
18 Completed Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
Conditions: HIV/HCV Co-infection;   HIV Infections
Interventions: Drug: Lopinavir/ritonavir;   Drug: Lopinavir/ritonavir with two nucleoside analogs
19 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
20 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years